Related Experiment Videos
Antipsychotics in clinical practice: guidelines for safe and effective use.
Stephen Curran1, Linda Harris, Andrew Macdonald
1University of Huddersfield, Queensgate; Consultant in Old Age Psychiatry, Wakefield and Pontefract Community Health NHS Trust, Fieldhead Hospital, Wakefield, UK. s.curran@hud.ac.uk
Human Psychopharmacology
|October 31, 2002
Summary
Newer atypical antipsychotic drugs effectively treat schizophrenia symptoms with fewer side effects. Despite higher costs, evidence shows atypical antipsychotics are cost-effective and improve patient quality of life.
Area of Science:
- Psychiatry
- Pharmacology
- Health Economics
Background:
- Antipsychotic medications are crucial for schizophrenia management.
- Older antipsychotics often cause significant adverse effects.
- Atypical antipsychotics offer improved efficacy and tolerability.
Purpose of the Study:
- To evaluate the cost-effectiveness of atypical antipsychotics compared to older drugs for schizophrenia.
- To assess the impact of atypical antipsychotics on patient quality of life.
- To highlight the need for a national consensus on atypical antipsychotic utilization.
Main Methods:
- Comparative analysis of treatment outcomes and side-effect profiles.
- Economic evaluation considering medication costs, healthcare utilization, and quality of life metrics.
- Review of existing evidence on atypical antipsychotic effectiveness.
Main Results:
- Atypical antipsychotics demonstrate efficacy in treating both positive and negative symptoms of schizophrenia.
- These newer agents exhibit a significantly reduced incidence of serious side-effects.
- When all factors are considered, atypical antipsychotics are proven to be cost-effective.
Conclusions:
- Atypical antipsychotics represent a cost-effective treatment option for schizophrenia, enhancing patient quality of life.
- Despite demonstrated benefits, there is considerable variability in the clinical use of these medications.
- A national consensus is urgently needed to standardize and optimize the use of atypical antipsychotics in schizophrenia care.